Daxor Corporation (DXR)
Market Cap | 41.19M |
Revenue (ttm) | 34.31M |
Net Income (ttm) | 5.75M |
Shares Out | 4.73M |
EPS (ttm) | 1.41 |
PE Ratio | 6.30 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 6,453 |
Open | 8.65 |
Previous Close | 8.38 |
Day's Range | 8.40 - 8.89 |
52-Week Range | 7.11 - 13.13 |
Beta | -0.49 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 a... [Read more]
Financial Performance
In 2023, Daxor's revenue was $34.59 million, an increase of 448.16% compared to the previous year's $6.31 million. Earnings were $280,640, a decrease of -94.58%.
Financial StatementsNews
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, an...
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
Oak Ridge, TN, March 22, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces an investor call to be held on Monday, March 25, ...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders ...
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in bloo...
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA...
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients
Only Daxor's BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global l...
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Technology and ...
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
Oak Ridge, TN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions wit...
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader i...
New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients
Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood vo...
Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
Leading Clinicians Highlight Significant Outcome Improvements with Daxor's Blood Volume Analysis Innovative Technology
New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
Blood Volume Analysis (BVA) in 83-Patient Study Provided Highly Effective Guidance for Care of Heart Failure Patients Otherwise Unavailable Using Common Proxy Diagnostic Methods
Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
Support for Development of Daxor's Non-Nuclear Tracer for Next Generation Blood Volume Analyzer Systems Aims to Deliver Gold Standard Accuracy with Increased Access, Ease of Use, and Frequency of Test...
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023
Daxor's Blood Volume Technology Featured at Scientific Session Oak Ridge, TN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technolo...
Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients
Oak Ridge, TN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Daxor C orporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the National Institutes of Health (NI...
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Oak Ridge, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh wi...
Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023
Net Assets Increases to $30.4 Million From $29.0 Million Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, ann...
JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®
Researchers Call for Larger Clinical Trial Citing Outcomes from Study Oak Ridge, TN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement te...
JACC-HF Study Compares Daxor's BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients
Volume and Pressure Measures are Complementary, Not Interchangeable Oak Ridge, TN, July 12, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement tech...
Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer
Oak Ridge, TN, July 05, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the United States Defense Health Agency...
Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering
Oak Ridge, TN, June 22, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that Maxim Group LLC (“Maxim”), as Represent...
Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference
Oak Ridge, TN, June 12, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that Michael Feldschuh, CEO and President ha...
Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering
Oak Ridge, TN, May 25, 2023 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of it...
Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering
Oak Ridge, TN, May 22, 2023 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of it...
Daxor stock tumbles 22% premarket after announcing plans to issue stock
Daxor Corp.'s stock DXR, -6.06% tumbled 22% premarket Monday, after the company announced plans to issue stock. The company, which is registered as a closed-end investment company to raise the funds f...